Clinical trials: Hidradenitis
Pyoderma Gangrenosum, Hidradenitis Suppurativa
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG).
- Conditions
- Pyoderma Gangrenosum, Hidradenitis Suppurativa, Psoriasis
- Trial name
- NCT04792957
- Testing
- immunohistochemical methods
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Dokuz Eylul University
Atopic Dermatitis, Dermatology
A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions
The primary goal of the study is to collect standardized patient and clinician reported outcome measures for patients diagnosed with a range of dermatological conditions in an academic clinical practice setting.
- Conditions
- Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata
- Trial name
- ClinPRO-DERM (NCT05084417)
- Testing
- N/A This is an observational study
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- OM1, Inc.
Adults With Moderate-to-severe Hidradenitis Suppurativa
QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa
This is a Phase II clinical study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of QLS12010 capsules in the treatment of moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- NCT07417917
- Testing
- QLS12010
- Volunteers
- 102 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hidradenitis Suppurativa, Atopic Dermatitis
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort.
- Trial name
- NCT06524635
- Testing
- Lutikizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- AbbVie
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Hidradenitis Suppurativa
Etanercept in Hidradenitis Suppurativa
The rationale of the protocol is based on the reported beneficiary results of case-patients by the administration of other anti-TNF drug (infliximab) in separate cases on the grounds of a probable autoimmune predisposition of the…
- Trial name
- NCT00329823
- Testing
- Etanercept sc 50mg per week for 12 weeks
- Where
- Greece
- Volunteers
- 10 people
- Sponsor
- University of Athens
Hidradenitis Suppurativa
Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa
The trial enrolls patients with moderate to severe Hidradenitis Suppurativa (HS). The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 weeks in these patients.
- Trial name
- NCT03001622
- Testing
- IFX-1
- Where
- Greece
- Volunteers
- 12 people
- Sponsor
- InflaRx GmbH
Hidradenitis Suppurativa
A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients
The goal of this clinical trial is to compare the efficacy secukimumab versus tofacitinib in patients with moderate to severe hidradenitis suppurativa (HS)in adults.
- Trial name
- NCT06707246
- Testing
- Secukinumab 300 MG; Tofacitinib 11mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hidradenitis Suppurativa
Hidradenitis Suppurativa Patient Experience With Humira Treatment
Hidradenitis suppurativa (HS) is a chronic relapsing condition with significant psychosocial impact and morbidity, but that doesn't mean that patients will necessarily be adherent to recommended treatments.
- Trial name
- NCT04132388
- Testing
- Electronic Reporting, Adalimumab
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Hidradenitis Suppurativa
Treatment of Hidradenitis Suppurativa Using Etanercept
Therapy with etanercept, a TNF inhibitor will reverse the inflammation, symptoms and quality of life and allow healing of HS.
- Trial name
- NCT00949546
- Testing
- etanercept
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Penn State University